HK1256595A1 - Method for preparing ophthalmic preparation containing thymosin beta-4 - Google Patents

Method for preparing ophthalmic preparation containing thymosin beta-4 Download PDF

Info

Publication number
HK1256595A1
HK1256595A1 HK18115713.4A HK18115713A HK1256595A1 HK 1256595 A1 HK1256595 A1 HK 1256595A1 HK 18115713 A HK18115713 A HK 18115713A HK 1256595 A1 HK1256595 A1 HK 1256595A1
Authority
HK
Hong Kong
Prior art keywords
thymosin
composition
container
ophthalmic preparation
inert gas
Prior art date
Application number
HK18115713.4A
Other languages
English (en)
Chinese (zh)
Inventor
Si Young Lee
Sin Wook Kang
Ji Hye SUNG
Tae Heum UM
Original Assignee
HLB Therapeutics Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HLB Therapeutics Co., Ltd. filed Critical HLB Therapeutics Co., Ltd.
Publication of HK1256595A1 publication Critical patent/HK1256595A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B23/00—Noble gases; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A61J1/12—Bag-type containers with means for holding samples of contents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
HK18115713.4A 2015-10-06 2015-12-18 Method for preparing ophthalmic preparation containing thymosin beta-4 HK1256595A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150140489 2015-10-06
KR10-2015-0140489 2015-10-06
PCT/KR2015/013981 WO2017061663A1 (ko) 2015-10-06 2015-12-18 티모신 베타 4를 포함하는 안약의 제조방법

Publications (1)

Publication Number Publication Date
HK1256595A1 true HK1256595A1 (en) 2019-09-27

Family

ID=58487995

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115713.4A HK1256595A1 (en) 2015-10-06 2015-12-18 Method for preparing ophthalmic preparation containing thymosin beta-4

Country Status (6)

Country Link
US (1) US10744088B2 (enExample)
EP (1) EP3342398A4 (enExample)
JP (2) JP6996713B2 (enExample)
KR (1) KR102487614B1 (enExample)
HK (1) HK1256595A1 (enExample)
WO (1) WO2017061663A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
CA3114204A1 (en) * 2018-10-10 2020-04-16 Presbyopia Therapies, Inc. Compositions and methods for the treatment of presbyopia
CN112107678B (zh) * 2020-09-30 2022-11-18 辰欣药业股份有限公司 一种含有胸腺法新的冻干组合物及其制备方法
US12180206B2 (en) 2021-11-17 2024-12-31 Lenz Therapeutics Operations, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150744A (en) * 1976-02-27 1979-04-24 Smith & Nephew Pharmaceuticals Ltd. Packaging
US6271216B1 (en) * 1989-07-24 2001-08-07 Allergan Stable solution of hyaluronate in a balanced salt medium
KR19980703582A (ko) * 1995-04-04 1998-11-05 가와구치 시게키 염산 프로카테롤 수용액 제제를 보지하는 패키지 및 염산 프로카테롤 수용액 제제
CA2338928A1 (en) 1998-07-30 2000-02-10 Hynda K. Kleinman Thymosin .beta.4 promotes wound repair
MXPA01003729A (es) * 1998-10-14 2002-05-06 Kyowa Hakko Kogyo Kk Metodo para estabilizar una solucion acuosa de derivados de pirazoloacridona.
MX2007001181A (es) * 2004-07-30 2007-03-21 Otsuka Pharma Co Ltd Botella comprimible y envase con gotero oftalmico que usa el mismo.
CN1748704B (zh) * 2004-09-15 2011-05-04 尼普洛株式会社 注射用水溶液制剂及其稳定化方法
CA2612522A1 (en) * 2005-06-17 2006-12-28 Regenerx Biopharmaceuticals, Inc. Lkktet and/or lkktnt peptide compositions and methods
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
WO2008108927A2 (en) * 2007-03-06 2008-09-12 Regenerx Biopharmaceuticals, Inc. Methods and compositions for stabilizing polypeptides
MX2009010977A (es) 2007-04-11 2010-02-12 Biomarin Pharm Inc Metodos de administracion de tetrahidrobiopterina, composiciones asociadas y metodos de medicion.
JP5990880B2 (ja) * 2011-08-31 2016-09-14 東レ株式会社 有用タンパク質組成物およびその製造方法

Also Published As

Publication number Publication date
EP3342398A1 (en) 2018-07-04
JP2020183391A (ja) 2020-11-12
JP6996713B2 (ja) 2022-02-04
KR20170041109A (ko) 2017-04-14
EP3342398A4 (en) 2019-03-20
US20180228729A1 (en) 2018-08-16
JP2018531905A (ja) 2018-11-01
KR102487614B1 (ko) 2023-01-12
WO2017061663A1 (ko) 2017-04-13
US10744088B2 (en) 2020-08-18

Similar Documents

Publication Publication Date Title
US10744088B2 (en) Method for preparing ophthalmic preparation containing thymosin beta-4
EP0838221B1 (en) Lyophilized hgf preparations
EP2618814B1 (en) Caspofungin composition
CA2191317A1 (en) A pharmaceutical preparation comprising glucagon
IL218504A (en) Use of lkktet and / or lkktnt peptides to treat dry eye syndrome
JPH10212241A (ja) Ｂｄｎｆを安定に含有する製剤
KR20190137788A (ko) 안정한 펩타이드 조성물
CN1315531C (zh) 用于眼睛干燥及与眼睛干燥相关的疾病的治疗剂
EP2779993B1 (en) Autoclavable suspensions of cyclosporin a form 2
EP2496246B1 (en) Composition, method, and kit for alpha-1 proteinase inhibitor
EP3715451A2 (en) Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
KR101322527B1 (ko) 잔탄 검 및 테르페노이드를 포함하는 점안제
KR101838759B1 (ko) 점안제
US20250161403A1 (en) Peptides and methods of use thereof in treating ocular disorders
KR20170021745A (ko) 티모신 β4 및 시트르산을 유효성분으로 포함하는 각막 손상 예방 또는 치료용 조성물
EP4279066A1 (en) Ophthalmic composition including tanfanercept and exhibiting stability without use of stabilizer
EP3287141A1 (en) Nerve growth factor composition and powder injection
EP2704747B1 (en) Eye drops for treatment of conjunctivochalasis
KR100671449B1 (ko) 송아지의 제단백 혈액 추출물을 함유하는 점안용 액제조성물
EP4609874A1 (en) Pharmaceutical composition comprising echinocandin analog and preparation method for pharmaceutical composition
US20230079395A1 (en) Ophthalmic pharmaceutical composition and use thereof
HK1256177A1 (en) Lkktet and/or lkktnt peptide compositions which are lyophilized or in a form capable of being lyophilized
KR20170021667A (ko) 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
HK1172820A (en) Eye drops
HK1202078B (en) Autoclavable suspensions of cyclosporin a form 2